Article Data

  • Views 558
  • Dowloads 136

Original Research

Open Access

Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer

  • M. Matoda1,*,
  • K. Omatsu1
  • A. Yamamoto1
  • H. Nomura1
  • T. Tanigawa1
  • Y. Kawamata1
  • K. Kato1
  • K. Umayahara1
  • N. Takeshima1

1Department of Gynecology Cancer Institute Hospital, Tokyo (Japan)

DOI: 10.12892/ejgo24392014 Vol.35,Issue 3,May 2014 pp.224-229

Published: 10 May 2014

*Corresponding Author(s): M. Matoda E-mail: maki.matsumura@jfcr.or.jp

Abstract

Purpose: To investigate the effectiveness of platinum-based combination chemotherapy as second-line chemotherapy for patients with advanced or recurrent endometrial cancer treated initially by platinum-based combination chemotherapy. Materials and Methods: Subjects were patients who had received platinum-based combination chemotherapy as second-line chemotherapy: 56 patients with recurrent disease who had previously received postoperative adjuvant platinum-based combination chemotherapy (Category 1) and 21 patients who had received first-line chemotherapy but not adjuvant chemotherapy for advanced or recurrent disease (Category 2). Patients’ records were searched for the response to second-line chemotherapy and survival, particularly in relation to the platinum-free interval (PFI). Results: A PFI over 12 months was a predictor of response (64.7%) and overall survival time (23 months) in Category 1 patients. A PFI of less than three months was a negative predictor of response (0%) and overall survival (nine months) in Category 2 patients. Conclusion: Platinum-based combination chemotherapy appears to be effective as second-line chemotherapy for endometrial cancer if the PFI is sufficiently long.

Keywords

Second-line chemotherapy; Advanced and recurrent endometrial cancer; Platinum-free interval.


Cite and Share

M. Matoda,K. Omatsu,A. Yamamoto,H. Nomura,T. Tanigawa,Y. Kawamata,K. Kato,K. Umayahara,N. Takeshima. Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer. European Journal of Gynaecological Oncology. 2014. 35(3);224-229.

References

[1] Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E, Carson L.F., Evers C.: “A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study”. J. Clin. Oncol., 1994, 12, 1408.

[2] Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A. et al..: “Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group study”. J. Clin. Oncol. 2004, 22, 3902.

[3] Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L. et al.: “Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: A Gynecologic Oncology Group study”. Ann. Oncol. 2004, 15, 1173.

[4] Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R. et al.: “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study”. J. Clin. Oncol. 2004, 22, 2159.

[5] Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S. et al.: “Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin”. J. Clin. Oncol. 1991, 9, 389.

[6] Moore K.N., Tian C., McMeekin D.S., Thigpen J.T., Randall M.E., Gallion H.H.: “Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? A Gynecologic Oncology Group ancillary data analysis”. Cancer, 2010, 116, 5407.

[7] Rose P.G., Blessing J.A., Lewandowski G.A., Creasman W.T., Webster K.D.: “A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study”. Gynecol. Oncol., 1996, 63, 101.

[8] Lincoln S., Blessing J.A., Lee R.B., Rocereto T.F.: “Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study”. Gynecol. Oncol., 2003, 88, 277.

[9] Moore D.H., Blessing J.A., Dunton C., Buller R.E., Reid G.C.: “Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group”. Gynecol. Oncol., 1999, 75, 473.

[10] Muggia F.M., Blessing J.A., Sorosky J., Reid G.C.: “Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2002, 20, 2360.

[11] Plaxe S., Blessing J.A., Husseindazeh N., Webster K.D., Rader J. S., Dunton C.J.: “Phase II trial of pyrazoloacridine in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study”. Gynecol. Oncol., 2002, 84, 241.

[12] Miller D.S., Blessing J.A., Lentz S.S., Waggoner S.E.: “A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2002, 87, 247.

[13] Fracasso P.M., Blessing J.A., Molpus K.L., Adler L.M., Sorosky J. I., Rose P.G.: “Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2006, 103, 523.

[14] Schilder R., Blessing J.A., Pearl M.L., Rose P.G.: “Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group”. Invest. New Drugs, 2004, 22, 343.

[15] Grendys E.C. Jr., Blessing J.A., Burger R., Hoffman J.: “A phase II evaluation of flavorpiridol as second-line chemotherapy of en-dometrial carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2005, 98, 249.

[16] Aghajanian C., Sill M.W., Dancy K.M., Greer B., McMeekin D.S., Rose P.G. et al.: “Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2011, 29, 2259.

[17] Oza A.M., Elit L., Tsao M.S., Kamel-Reid S., Biagi J., Provencher D. M. et al.: “Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group”. J. Clin. Oncol., 2001, 29, 3278.

[18] Alvarez E.A., Brady W.E., Walker J.L., Rotmensch J., Zhou X.C., Kendrick J.E. et al.: “Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2013, 129, 22. doi: 10.1016/j.ygyno.2012.12.022. Epub 2012 Dec 20.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top